Immunic (NASDAQ:IMUX – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Friday.
Separately, Brookline Capital Management restated a “buy” rating and set a $10.00 price target on shares of Immunic in a research note on Friday, April 5th.
Get Our Latest Stock Analysis on IMUX
Immunic Price Performance
Immunic (NASDAQ:IMUX – Get Free Report) last released its quarterly earnings data on Thursday, February 22nd. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.03. Analysts anticipate that Immunic will post -0.99 earnings per share for the current year.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the business. LPL Financial LLC acquired a new position in shares of Immunic during the 2nd quarter worth $28,000. MetLife Investment Management LLC bought a new stake in shares of Immunic during the 1st quarter worth $134,000. JPMorgan Chase & Co. boosted its holdings in shares of Immunic by 21.2% during the 1st quarter. JPMorgan Chase & Co. now owns 13,649 shares of the company’s stock worth $154,000 after buying an additional 2,387 shares during the period. Two Sigma Securities LLC bought a new stake in shares of Immunic during the 2nd quarter worth $36,000. Finally, Wolverine Trading LLC bought a new stake in Immunic in the 2nd quarter valued at $42,000. Institutional investors and hedge funds own 51.82% of the company’s stock.
About Immunic
Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Featured Articles
- Five stocks we like better than Immunic
- What is the S&P/TSX Index?
- Comprehensive Analysis of PayPal Stock
- Stock Splits, Do They Really Impact Investors?
- Intuitive Surgical Stock Can Trend Much Higher This YearÂ
- Trading Halts Explained
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.